India, June 2 -- Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the treatment of obesity.
COURAGE study was designed to investigate the quality of weight loss in patients with obesity. The treatment is divided into two phases, each lasting 26 weeks. This includes a weight loss phase and a weight maintenance phase. During the weight-loss phase, patients were randomized to receive either Novo Nordisk's semaglutide (GLP-1 receptor agonist) alone or in combination with two different doses of trevogrumab (anti-GDF8/anti-myostatin), or higher-dose trevogrumab plus garetosmab (anti-activin A).
Interim results from ...